Propofol Dose-Finding for Colonoscope Insertion in Geriatric Patients
Estimation of the ED50 of Propofol for Successful Colonoscope Insertion in Geriatric Patients: A Prospective Dose-finding Study
1 other identifier
interventional
29
1 country
1
Brief Summary
The aim of this prospective dose-finding study is to determine the ED50 of propofol required for successful colonoscope insertion in geriatric patients. The study is designed using Dixon's up-and-down sequential allocation method. Successful colonoscope insertion is defined as the absence of pain, movement, or vocal response, together with a MOAA/S score ≤2 at the second minute after induction, and maintained until the colonoscope pass the rectosigmoid junction. In cases of failure, an additional dose of propofol is administered, and the initial dose for the next patient was increased by 0.1 mg/kg. In cases of success, the initial dose for the next patient was decreased by 0.1 mg/kg. The primary outcome is the determination of the ED50 of propofol for successful colonoscope insertion until passage of the rectosigmoid junction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2025
CompletedStudy Start
First participant enrolled
September 8, 2025
CompletedFirst Posted
Study publicly available on registry
September 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 8, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 8, 2025
CompletedNovember 17, 2025
November 1, 2025
1 month
August 25, 2025
November 14, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
ED50
The median effective dose (ED50) of propofol required for successful colonoscope insertion in geriatric patients will be determined using the modified Dixon's up-and-down method. Successful insertion is defined as the absence of movement or vocalization and a MOAA/S score ≤2 within 2 minutes after induction, maintained until the colonoscope passes the rectosigmoid junction.
At 2 minutes after induction (during colonoscope insertion)
Secondary Outcomes (9)
ED95
At 2 minutes after induction (during colonoscope insertion)
Additional propofol dose
The cumulative amount of rescue propofol administered during the procedure will be recorded.
total propofol dose
The cumulative amount of total propofol administered during the procedure will be recorded.
Presence of pain during propofol injection
Immediately after first propofol administration
Heart rate
Baseline (before sedation), at colonoscope insertion, 2 minutes after insertion, and at the end of the procedure
- +4 more secondary outcomes
Study Arms (1)
Group mono-Propofol
OTHERThe study is designed using Dixon's up-and-down sequential allocation method. Successful colonoscope insertion is defined as the absence of pain, movement, or vocal response, together with a MOAA/S score ≤2 at the second minute after induction, and maintained until the colonoscope passes the rectosigmoid junction. In cases of failure, an additional dose of propofol is administered, and the initial dose for the next patient is increased by 0.1 mg/kg. In cases of success, the initial dose for the next patient is decreased by 0.1 mg/kg.
Interventions
The initial dose is 1.5 mg/kg, adjusted in increments or decrements of 0.1 mg/kg according to the modified Dixon's up-and-down method. Additional rescue doses of 0.25-0.5 mg/kg are titrated if insertion is unsuccessful.
Eligibility Criteria
You may qualify if:
- Patients who provided informed consent to participate
- Patients scheduled for colonoscopy
- ASA physical status I-III
- Male and female patients aged ≥65 years
You may not qualify if:
- Patients who did not provide consent
- Known allergy to propofol
- Body weight \<40 kg
- Body mass index (BMI) \>30 kg/m²
- Presence of acute or chronic pain
- Chronic alcohol consumption
- Use of antipsychotic, antidepressant, or hypnotic medications
- Patients with obstructive sleep apnea syndrome (STOP-Bang score ≥3)
- Patients with known anorectal diseases such as hemorrhoids, anal fissure, or anal fistula
- History of oncological disease
- Uncontrolled hypertension (blood pressure \>180/110 mmHg)
- Severe hepatic or renal dysfunction
- Acute respiratory tract infection or other chronic respiratory disorders
- Patients with a history of colorectal surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Health Sciences Kocaeli City Hospital
Kocaeli, Izmit, 41100, Turkey (Türkiye)
Related Publications (1)
Liu FK, Wan L, Shao LJZ, Zou Y, Liu SH, Xue FS. Estimation of effective dose of propofol mono-sedation for successful insertion of upper gastrointestinal endoscope in healthy, non-obese Chinese adults. J Clin Pharm Ther. 2021 Apr;46(2):484-491. doi: 10.1111/jcpt.13312. Epub 2020 Nov 20.
PMID: 33217028BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bedirhan Günel
Kocaeli City Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 25, 2025
First Posted
September 9, 2025
Study Start
September 8, 2025
Primary Completion
October 8, 2025
Study Completion
October 8, 2025
Last Updated
November 17, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share